Literature DB >> 26179179

Optimal management of non-functioning pituitary adenomas.

Yona Greenman1, Naftali Stern.   

Abstract

Transsphenoidal surgery is the treatment of choice for large non-functioning pituitary adenomas (NFPA) and symptomatic patients. The therapeutic strategies for the management of NFPA after surgery, i.e., watchful waiting, irradiation, or medical therapy have not been compared by randomized controlled trials. Slow re-growth is common, but the natural history of untreated tumors is variable. Conservative follow-up is associated with progression rates of over 40 %. Radiation is highly effective in preventing residual tumor growth, but has serious long-term side effects. Finally, no medications are currently approved for the treatment of NFPA. In this review, we present our view of the optimal management of these tumors, which includes risk stratification for the identification of high-risk patients suitable for active intervention, leaving low-risk patients for careful monitoring.

Entities:  

Mesh:

Year:  2015        PMID: 26179179     DOI: 10.1007/s12020-015-0685-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  57 in total

Review 1.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

2.  Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.

Authors:  Claudia Ramírez; Sonia Cheng; Guadalupe Vargas; Sylvia L Asa; Shereen Ezzat; Baldomero González; Lourdes Cabrera; Gerardo Guinto; Moisés Mercado
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

3.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

Authors:  G Minniti; D Traish; S Ashley; A Gonsalves; M Brada
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

4.  Cabergoline and the risk of valvular lesions in endocrine disease.

Authors:  Patrizio Lancellotti; Elena Livadariu; Muriel Markov; Adrian F Daly; Maria-Cristina Burlacu; Daniela Betea; Luc Pierard; Albert Beckers
Journal:  Eur J Endocrinol       Date:  2008-05-02       Impact factor: 6.664

Review 5.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

6.  Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.

Authors:  T Lohmann; C Trantakis; M Biesold; S Prothmann; S Guenzel; R Schober; R Paschke
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

7.  Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.

Authors:  Y Greenman; G Ouaknine; I Veshchev; I I Reider-Groswasser; Y Segev; N Stern
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

Review 8.  Practical pituitary pathology: what does the pathologist need to know?

Authors:  Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

9.  Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

Review 10.  Nonfunctioning pituitary tumors and pituitary incidentalomas.

Authors:  Mark E Molitch
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

View more
  9 in total

Review 1.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

2.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

Review 3.  Non-functioning pituitary adenomas: growth and aggressiveness.

Authors:  Kristin Astrid Øystese; Johan Arild Evang; Jens Bollerslev
Journal:  Endocrine       Date:  2016-04-11       Impact factor: 3.633

Review 4.  Management of NFAs: medical treatment.

Authors:  Naomi Even-Zohar; Yona Greenman
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

5.  Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.

Authors:  Pedro Marques; Sayka Barry; Amy Ronaldson; Arla Ogilvie; Helen L Storr; Peter J Goadsby; Michael Powell; Mary N Dang; Harvinder S Chahal; Jane Evanson; Ajith V Kumar; Joan Grieve; Márta Korbonits
Journal:  Int J Endocrinol       Date:  2018-04-04       Impact factor: 2.803

6.  Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors.

Authors:  Pedro Marques; Francisca Caimari; Laura C Hernández-Ramírez; David Collier; Donato Iacovazzo; Amy Ronaldson; Kesson Magid; Chung Thong Lim; Karen Stals; Sian Ellard; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 6.134

7.  SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA.

Authors:  Xiaoyu Wang; Yuanjian Fang; Yunxiang Zhou; Xiaoming Guo; Ke Xu; Chenguang Li; Jianmin Zhang; Yuan Hong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-09       Impact factor: 5.555

8.  FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Authors:  Bin Zhu; Juan Wang; Lingling Qin; Lei Wang; Yanfei Zheng; Lei Zhang; Wei Wang
Journal:  Biosci Rep       Date:  2018-11-09       Impact factor: 3.840

9.  The Relationship Between Posterior Pituitary Bright Spot on Magnetic Resonance Imaging (MRI) and Postoperative Diabetes Insipidus for Pituitary Adenoma Patients.

Authors:  Shousen Wang; Kunzhe Lin; Deyong Xiao; Liangfeng Wei; Lin Zhao
Journal:  Med Sci Monit       Date:  2018-09-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.